Send us a text

In pharmaceutical and biotech manufacturing, artificial intelligence is no longer a future concept. It’s here, supporting product development, process control, and quality decisions in GMP-regulated environments. But with this opportunity comes significant responsibility. While AI offers powerful capabilities, it also introduces a new set of risks, ones that must be managed to meet compliance, safety, and quality expectations.

In this Quality Grind Short - Mike outlines both the risks and opportunities that AI provides, and highlights guidance being provided by global regulatory agencies. 

Contact MEDVACON:

• Message us at @MedvaconLifeSciences on LinkedIn
• Visit our website at www.medvacon.com/contact
• Email us at [email protected]

Thanks for listening! Don't forget to follow us @medvacon on all platforms for updates on blogs and podcasts!